{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:19:58Z","timestamp":1785860398400,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Grants-in-Aid for Science, Japan","award":["23EA1035"],"award-info":[{"award-number":["23EA1035"]}]},{"DOI":"10.13039\/501100004721","name":"University of Tokyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"publisher"}]},{"name":"St. Luke's International University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10147-025-02894-z","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:58:42Z","timestamp":1760500722000},"page":"2464-2473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world adherence to antiemetic guidelines in Japanese patients receiving high or carboplatin-based moderate emetic risk chemotherapy"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4732-3272","authenticated-orcid":false,"given":"Ayako","family":"Okuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinobu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Iino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadamoto","family":"Zenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Satomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2894_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10549-013-2727-3","volume":"142","author":"I Kuchuk","year":"2013","unstructured":"Kuchuk I, Bouganim N, Beusterien K et al (2013) Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat 142:101\u2013107. https:\/\/doi.org\/10.1007\/s10549-013-2727-3","journal-title":"Breast Cancer Res Treat"},{"key":"2894_CR2","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.21037\/apm-19-453","volume":"10","author":"T Smit","year":"2021","unstructured":"Smit T, Kotze I, du Plessis J (2021) The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy. Ann Palliat Med 10:2679\u20132686. https:\/\/doi.org\/10.21037\/apm-19-453","journal-title":"Ann Palliat Med"},{"key":"2894_CR3","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/nejmra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356\u20131367. https:\/\/doi.org\/10.1056\/nejmra1515442","journal-title":"N Engl J Med"},{"key":"2894_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08623-y","volume":"32","author":"MC Renaux Torres","year":"2024","unstructured":"Renaux Torres MC, Robinson PD, Sung L et al (2024) Outcomes of chemotherapy-induced nausea and vomiting guideline adherence in pediatric and adult patients: a systematic review. Support Care Cancer 32:455. https:\/\/doi.org\/10.1007\/s00520-024-08623-y","journal-title":"Support Care Cancer"},{"key":"2894_CR5","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the pan European emesis registry (PEER). Ann Oncol 23:1986\u20131992. https:\/\/doi.org\/10.1093\/annonc\/mds021","journal-title":"Ann Oncol"},{"key":"2894_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","volume":"47","author":"A Molassiotis","year":"2014","unstructured":"Molassiotis A, Aapro M, Dicato M et al (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 47:839-848.e4. https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.06.012","journal-title":"J Pain Symptom Manage"},{"key":"2894_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi Y, Chan S, McFarlane T et al (2019) ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27:87\u201395. https:\/\/doi.org\/10.1007\/s00520-018-4464-y","journal-title":"Support Care Cancer"},{"key":"2894_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol 26:1\u201317. https:\/\/doi.org\/10.1007\/s10147-020-01818-3","journal-title":"Int J Clin Oncol"},{"key":"2894_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00520-024-08462-x","volume":"32","author":"SKF Kennedy","year":"2024","unstructured":"Kennedy SKF, Goodall S, Lee SF et al (2024) 2020 ASCO, 2023 NCCN, 2023 MASCC\/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer 32:280. https:\/\/doi.org\/10.1007\/s00520-024-08462-x","journal-title":"Support Care Cancer"},{"key":"2894_CR10","first-page":"1683","volume":"46","author":"T Saeki","year":"2019","unstructured":"Saeki T (2019) The version 2.0 practice guideline for anti-emetic and standard therapy. Gan To Kagaku Ryoho 46:1683\u20131685","journal-title":"Gan To Kagaku Ryoho"},{"key":"2894_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/s1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242\u2013249. https:\/\/doi.org\/10.1016\/s1470-2045(19)30678-3","journal-title":"Lancet Oncol"},{"key":"2894_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","volume":"29","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M et al (2024) 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol 29:873\u2013888. https:\/\/doi.org\/10.1007\/s10147-024-02535-x","journal-title":"Int J Clin Oncol"},{"key":"2894_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10147-024-02663-4","volume":"30","author":"M Murakami","year":"2025","unstructured":"Murakami M, Miyata Y, Nakashima K et al (2025) Clinical benefits of adding olanzapine to 5-HT(3) receptor antagonist, NK(1) receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan Society of Clinical Oncology. Int J Clin Oncol 30:27\u201339. https:\/\/doi.org\/10.1007\/s10147-024-02663-4","journal-title":"Int J Clin Oncol"},{"key":"2894_CR14","doi-asserted-by":"publisher","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","volume":"15","author":"MJ Berger","year":"2017","unstructured":"Berger MJ, Ettinger DS, Aston J et al (2017) NCCN guidelines insights: antiemesis, version 2.2017. J Natl Compr Canc Netw 15:883\u2013893. https:\/\/doi.org\/10.6004\/jnccn.2017.0117","journal-title":"J Natl Compr Canc Netw"},{"key":"2894_CR15","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/jco.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240\u20133261. https:\/\/doi.org\/10.1200\/jco.2017.74.4789","journal-title":"J Clin Oncol"},{"key":"2894_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13716","volume":"26","author":"M Aapro","year":"2021","unstructured":"Aapro M, Scotte F, Escobar Y et al (2021) Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist 26:e1073\u2013e1082. https:\/\/doi.org\/10.1002\/onco.13716","journal-title":"Oncologist"},{"key":"2894_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2022.01.028","volume":"166","author":"M Aapro","year":"2022","unstructured":"Aapro M, Caprariu Z, Chilingirov P et al (2022) Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: results of the nausea\/emesis registry in oncology (NERO). Eur J Cancer 166:126\u2013133. https:\/\/doi.org\/10.1016\/j.ejca.2022.01.028","journal-title":"Eur J Cancer"},{"key":"2894_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1482","volume":"5","author":"A Okuyama","year":"2022","unstructured":"Okuyama A, Boku N, Higashi T (2022) Real-world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: a study based on a nationwide database. Cancer Rep (Hoboken) 5:e1482. https:\/\/doi.org\/10.1002\/cnr2.1482","journal-title":"Cancer Rep (Hoboken)"},{"key":"2894_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamaoncol.2016.4096","volume":"3","author":"A Okuyama","year":"2017","unstructured":"Okuyama A, Nakamura F, Higashi T (2017) Prescription of prophylactic antiemetic drugs for patients receiving chemotherapy with minimal and low emetic risk. JAMA Oncol 3:344\u2013350. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4096","journal-title":"JAMA Oncol"},{"key":"2894_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s00520-024-08367-9","volume":"32","author":"R Lee","year":"2024","unstructured":"Lee R, Ku M, Je NK (2024) Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea. Support Care Cancer 32:190. https:\/\/doi.org\/10.1007\/s00520-024-08367-9","journal-title":"Support Care Cancer"},{"key":"2894_CR21","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.21873\/invivo.11611","volume":"33","author":"I Yoshida","year":"2019","unstructured":"Yoshida I, Tamura K, Miyamoto TY et al (2019) Prophylactic antiemetics for haematological malignancies: prospective nationwide survey subset analysis in Japan. In Vivo 33:1355\u20131362. https:\/\/doi.org\/10.21873\/invivo.11611","journal-title":"In Vivo"},{"key":"2894_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/cas.12837","volume":"107","author":"M Iwamoto","year":"2016","unstructured":"Iwamoto M, Nakamura F, Higashi T (2016) Monitoring and evaluating the quality of cancer care in Japan using administrative claims data. Cancer Sci 107:68\u201375. https:\/\/doi.org\/10.1111\/cas.12837","journal-title":"Cancer Sci"},{"key":"2894_CR23","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2025.0560","volume":"333","author":"SY Kim","year":"2025","unstructured":"Kim SY, Park HS, Chiang AC (2025) Small cell lung cancer: a review. JAMA 333:1906\u20131917. https:\/\/doi.org\/10.1001\/jama.2025.0560","journal-title":"JAMA"},{"key":"2894_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamaoncol.2015.3730","volume":"2","author":"M Clemons","year":"2016","unstructured":"Clemons M, Bouganim N, Smith S et al (2016) Risk model-guided antiemetic prophylaxis vs physician\u2019s choice in patients receiving chemotherapy for early-stage breast cancer: a randomized clinical trial. JAMA Oncol 2:225\u2013231. https:\/\/doi.org\/10.1001\/jamaoncol.2015.3730","journal-title":"JAMA Oncol"},{"key":"2894_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/1078155212457966","volume":"19","author":"M Aseeri","year":"2013","unstructured":"Aseeri M, Mukhtar A, AI Khansa S et al (2013) A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center. J Oncol Pharm Pract 19:138\u2013144. https:\/\/doi.org\/10.1177\/1078155212457966","journal-title":"J Oncol Pharm Pract"},{"key":"2894_CR26","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1007\/s00520-019-04697-1","volume":"27","author":"P Dielenseger","year":"2019","unstructured":"Dielenseger P, B\u00f6rjeson S, Vidall C et al (2019) Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey. Support Care Cancer 27:4099\u20134106. https:\/\/doi.org\/10.1007\/s00520-019-04697-1","journal-title":"Support Care Cancer"},{"key":"2894_CR27","unstructured":"Zenda S (2022) Research that contributes to the realization of equalization of supportive care among cancer treatment base hospitals and other facilities. Health and Labour Sciences Research Grant (21EA1006). https:\/\/mhlw-grants.niph.go.jp\/project\/162176"},{"key":"2894_CR28","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/jjco\/hyab036","volume":"51","author":"A Okuyama","year":"2021","unstructured":"Okuyama A, Tsukada Y, Higashi T (2021) Coverage of the hospital-based cancer registries and the designated cancer care hospitals in Japan. Jpn J Clin Oncol 51:992\u2013998. https:\/\/doi.org\/10.1093\/jjco\/hyab036","journal-title":"Jpn J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02894-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02894-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02894-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:02:46Z","timestamp":1764021766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02894-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2894"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02894-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hirotoshi Iihara had a leadership position at AstraZeneca K.K., Eisai Co., Ltd., Daiichi-Sankyo Co., Ltd., and Taiho Pharmaceutical Co., Ltd. and received honoraria from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Sawai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., and Ohara Pharmaceutical Co., Ltd.. Nobuyuki Yamamoto received honoraria from MSD K.K., Accuray Japan K.K., AstraZeneca K.K., Abbvie Inc., Amgen Inc., Ono Pharmaceutical Co., Ltd., Guardant Health Japan Corp., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Chugai Foundation for Innovative Drug Discovery Science, Lao Tsumura Co., Ltd., Terumo Corporation, Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Novartis AG, Pfizer Global Supply Japan Inc., Merck Biopharma Co., Ltd, Janssen Pharmaceutical K.K., and USACO Corporation, as well as legal fees in case of lawsuit from Taiho Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan, Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Nippon Kayaku Co., Ltd., Prime Research Institute for Medical RWD, Inc., AstraZeneca K.K., and A2 Healthcare Co.. Eriko Satomi received honoraria from Shionogi & Co., Ltd, Tsumura & Co., Daiichi-Sankyo Co., Ltd., and Hisamitsu Pharmaceutical CO., Inc..","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of the National Cancer Center in Japan (2023\u2013383) and the Committee of Data Use for Quality Indicator project at the National Cancer Center in Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Due to the retrospective nature of the data, the project outlines were made public to provide patients with the opportunity to decline participation according to the National Ethics Guidelines for Medical Research on Human Participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}